Innogenetics Reports Results for the First Half of 2003 in Line with Expectations
19 août 2003 03h39 HE
|
Innogenetics
GENT, Belgium, Aug. 19, 2003 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced its unaudited results for the first half ending June 30, 2003.
First half 2003 highlights (versus first...
Innogenetics Reports Results for the First Quarter of 2003 in Line with Expectations
15 mai 2003 03h53 HE
|
Innogenetics
GENT, Belgium, May 15, 2003 (PRIMEZONE) -- Innogenetics today announced its results for the first quarter ending March 31, 2003.
First quarter 2003 highlights (versus first quarter 2002)
-...
Innogenetics Announces Positive Results in Pivotal Preclinical Study in Sepsis
06 mai 2003 02h45 HE
|
Innogenetics
GENT, Belgium, May 6, 2003 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today reported the results of its pivotal preclinical evaluation of a proprietary anti-inflammatory monoclonal antibody, INNO...
Innogenetics' Outlook for 2003 -- Enhanced Financial Prospects and Promising New Therapeutic Developments
15 janv. 2003 02h21 HE
|
Innogenetics
GENT, Belgium, Jan. 15, 2003 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced the preliminary indications of its year 2002 financial results, offered an initial outlook for 2003 and...
Innogenetics Reports Profitable Diagnostics Activities and Increased R&D Investments for the First Nine Months of 2002
15 nov. 2002 04h09 HE
|
Innogenetics
GENT, Belgium, Nov. 15, 2002 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced its results for the first nine months ending September 30, 2002.
Highlights
-- Diagnostics Division...
Innogenetics Announces Positive Liver Histology Results of Its Hepatitis C Therapeutic Vaccine
17 oct. 2002 03h51 HE
|
Innogenetics
GENT, Belgium, Oct. 17, 2002 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced the first liver histology results of its E1-based therapeutic candidate vaccine in 24 patients chronically...